Abivax Slides 4% as Investors Digest Half-Year Results and Executive Changes

Abivax (ABVX) is down 4.0% today. Here is some analysis on what might have caused this price movement.

Analysis: The pullback appears tied to investor reaction to Abivax’s first-half 2026 update, which paired a wider net loss with a senior medical leadership transition. The company also highlighted a strong cash position and a runway into late 2029, so the decline may reflect profit-taking and mixed interpretation of the update rather than a single clearly negative surprise.

Details:

Abivax released business updates and first-half 2026 financial results on September 21, 2026, putting the stock in focus for today’s session.

The company said Chief Medical Officer Fabio Cataldi will leave in the fourth quarter of 2026, with Chris Rabbat set to succeed him, while Tim Kelly was appointed chief technical officer.

For the second quarter, net loss widened to about 117.4 million euros from about 48.4 million euros a year earlier; for the first half, net loss widened to about 165.9 million euros from about 100.8 million euros.

Abivax said it had 402.4 million euros in cash, cash equivalents, and short-term investments as of June 30, and that July financing proceeds extended its expected cash runway into the fourth quarter of 2029.

Sources:

Abivax, SEC, MarketScreener

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$ABVX Hedge Fund Activity

We have seen 189 institutional investors add shares of $ABVX stock to their portfolio, and 165 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

HELIKON INVESTMENTS LTD added 2,787,131 shares (+inf%) to their portfolio in Q2 2026, for an estimated $371,413,077
UBS GROUP AG removed 2,702,488 shares (-59.4%) from their portfolio in Q2 2026, for an estimated $360,133,550
RA CAPITAL MANAGEMENT, L.P. added 1,132,557 shares (+inf%) to their portfolio in Q2 2026, for an estimated $150,924,545
NORGES BANK added 1,100,000 shares (+inf%) to their portfolio in Q2 2026, for an estimated $146,586,000
FMR LLC removed 1,094,684 shares (-85.1%) from their portfolio in Q2 2026, for an estimated $145,877,589
BAKER BROS. ADVISORS LP removed 875,796 shares (-100.0%) from their portfolio in Q2 2026, for an estimated $116,708,574
VESTAL POINT CAPITAL, LP added 849,443 shares (+56.6%) to their portfolio in Q2 2026, for an estimated $113,196,774

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$ABVX Analyst Ratings

Wall Street analysts have issued reports on $ABVX in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

BTIG issued a "Buy" rating on 06/30/2026

To track analyst ratings and price targets for $ABVX, check out Quiver Quantitative's $ABVX forecast page.

$ABVX Price Targets

Multiple analysts have issued price targets for $ABVX recently. We have seen 8 analysts offer price targets for $ABVX in the last 6 months, with a median target of $156.5.

Here are some recent targets:

Allison Bratzel from Piper Sandler set a target price of $175.0 on 07/09/2026
Gregory Renza from Truist Securities set a target price of $155.0 on 07/02/2026
Jason N. Butler from Citizens set a target price of $187.0 on 07/01/2026
Julian Harrison from BTIG set a target price of $175.0 on 06/30/2026
David Nierengarten from Wedbush set a target price of $110.0 on 06/30/2026
Thomas Smith from Leerink Partners set a target price of $148.0 on 06/30/2026
Faisal Khurshid from Jefferies set a target price of $158.0 on 06/30/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.